Triple GIP/GLP-1/Glucagon Receptor AgonistInvestigational

Retatrutide Dosage Calculator

Retatrutide is an investigational triple-agonist peptide (GIP/GLP-1/glucagon receptor) currently in Phase 3 clinical trials for obesity and type 2 diabetes. It is not yet FDA-approved or commercially available. Clinical trials have studied retatrutide at doses up to 12 mg weekly, showing significant weight loss results. This calculator provides educational dose-to-unit conversions based on published clinical trial concentrations for informational purposes only.

Retatrutide is an investigational medication currently in clinical trials. It has not been approved by the FDA for any indication. Information presented is based on published clinical trial data and is for educational purposes only.

050100

How many units is 1 mg of Retatrutide at 2 mg/mL?

Draw

50units

0.50 mL on a U-100 insulin syringe

1 mg ÷ 2 mg/mL × 100 = 50 units

For educational purposes only. Always follow your provider's instructions.

Quick Reference Table

All dose × concentration combinations

Dose2 mg/mL5 mg/mL10 mg/mL
1 mg502010
2 mg100*4020
4 mg200*80*40
8 mg400*160*80*
12 mg600*240*120*

Values in U-100 insulin syringe units

* Exceeds 50 units (0.5 mL) — may require splitting into two injections

There's an easier way

Tired of calculating doses?

We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.

Get Started

2-min quiz · Free consultation · No commitment

Clinical Trial Protocol

Phase 2 Trial · 24.2% weight loss at 48 weeks

Retatrutide

Phase 2 Clinical Trial·Once weekly
WeeksDosePhase
1-41 mgInitiation
5-82 mgEscalation
9-124 mgEscalation
13-168 mgEscalation
17+12 mgMaximum

Frequently Asked Questions

Retatrutide (LY3437943) is a triple-agonist peptide that activates three receptors: GIP, GLP-1, and glucagon. While semaglutide targets GLP-1 alone and tirzepatide targets GIP and GLP-1, retatrutide adds glucagon receptor activation, which may enhance fat burning and energy expenditure. This triple mechanism showed the most potent weight loss results of any obesity medication studied to date.

Phase 2 trials tested retatrutide at doses of 1 mg, 4 mg, 8 mg, and 12 mg administered once weekly via subcutaneous injection. The dose escalation started at lower levels and increased over several weeks, similar to the approach used with semaglutide and tirzepatide. The 12 mg dose produced the greatest weight loss in trial participants.

In the Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose (12 mg) lost an average of 24.2% of body weight over 48 weeks. This exceeded results seen with semaglutide (approximately 15-17%) and tirzepatide (approximately 20-22%) in their respective trials, though direct head-to-head comparisons have not been conducted.

Retatrutide is currently in Phase 3 clinical trials conducted by Eli Lilly. If trials are successful, an FDA submission could follow, but no specific approval timeline has been announced. Optimistic estimates suggest a potential approval in 2026 or 2027, though regulatory timelines are uncertain. Weight Method will provide updates as retatrutide progresses through the approval process.

No. Retatrutide is an investigational drug and has not received FDA approval for any indication. It is only available to participants enrolled in authorized clinical trials. Any product sold online claiming to be retatrutide outside of a clinical trial setting is unregulated and potentially dangerous.

Semaglutide is a single GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide is a triple GIP/GLP-1/glucagon agonist. Each additional receptor target appears to enhance weight loss efficacy. Clinical trial data suggests retatrutide produces the most weight loss of the three, but it lacks the long-term safety data and real-world evidence that semaglutide and tirzepatide have accumulated.

Clinical trials reported side effects similar to other GLP-1 medications: nausea, diarrhea, vomiting, and constipation, most commonly during dose escalation. The glucagon receptor component may also cause mild increases in heart rate. Most side effects were mild to moderate and decreased over time. Long-term safety data is still being collected in ongoing Phase 3 trials.

Based on clinical trial protocols, if retatrutide were compounded at 10 mg/mL, then: 1 mg = 10 units, 4 mg = 40 units, 8 mg = 80 units, and 12 mg = 120 units (1.2 mL, requiring a larger syringe). At 20 mg/mL: 4 mg = 20 units, 8 mg = 40 units, 12 mg = 60 units. These are hypothetical calculations — actual compounding concentrations will depend on future formulations.

No. Retatrutide is not available from compounding pharmacies, and no legitimate pharmacy can legally compound it at this time. The drug is only accessible through Eli Lilly's authorized clinical trials. Be wary of any online source claiming to sell retatrutide — such products are unverified and may contain harmful substances.

A triple agonist activates three hormone receptors simultaneously. Retatrutide targets GIP (improves insulin response and may enhance fat metabolism), GLP-1 (reduces appetite and slows gastric emptying), and glucagon (increases energy expenditure and promotes fat breakdown). The combination addresses weight loss from multiple biological pathways, which is believed to explain the stronger results seen in clinical trials compared to single or dual agonists.

Related Pages

Retatrutide DosingRetatrutide Side Effects

Dose-Specific Calculators

1 mg Retatrutide2 mg Retatrutide4 mg Retatrutide8 mg Retatrutide12 mg Retatrutide

Other Calculators

Semaglutide CalculatorTirzepatide Calculator

Dosage Guides

U100 Insulin Syringe Glp1 InjectionsConvert Milligrams To Units Glp1 VialCompounded Glp1 Vial ConcentrationsCompounded Glp1 Vial Vs Brand Name PenSame Syringe Different Glp1 MedicationsSemaglutide Vs Tirzepatide Dosing Comparison

All Dosage Calculators

Calculator Hub

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.